Biosynth

Biosynth manufactures critical chemical, peptide, and biological raw materials and provides custom synthesis and manufacturing services for pharmaceutical, vaccine, diagnostic, and life science programmes. Its capabilities span complex chemicals, peptides, bioconjugation, and biologics, combining research products with development and production work. Core chemistry expertise includes carbohydrates, nucleosides, enzyme substrates, active pharmaceutical ingredients, intermediates, specialty polymers, and reagents. The biologics portfolio covers antibodies, antigens, proteins, enzymes, plasma, and diagnostic reagents, alongside custom monoclonal and polyclonal antibody production, epitope mapping, and enzyme development. Peptide activities extend from lead discovery, optimization, and library production to neoantigen, therapeutic, and vaccine projects, using phage display and CLIPS™ technology for constrained peptide binders.

Founded in 1966, the company operates laboratories, manufacturing operations, warehouses, and distribution resources across Europe, Asia, and North America. Chemical production ranges from milligram quantities to multi-ton scale, with ISO 9001 and GMP manufacturing capabilities, analytical development, quality control, quality assurance, and regulatory support. Peptide production covers research, clinical, and multikilogram GMP requirements, while biological operations support in vitro diagnostic development and supply. Its integrated chemistry and biocatalysis teams can combine synthetic and enzyme-based production routes for demanding materials. Biosynth supplies customers in pharmaceuticals, diagnostics, biotechnology, research, food, agrochemistry, and cosmetics, supported by a global distribution network and a research portfolio of more than one million products.